Evaluation of a Matrix Tablet Prepared with Polyacrylamide-g-Sodium Alginate Co-polymers and Their Partially Hydrolyzed Co-polymers for Sustained Release of Diltiazem Hydrochloride

Sustained release Carvedilol matrix tablets constituting Kollidon SR were developed in this study in an attempt to investigate the effect of release modifiers on the release profile of Carvedilol from matrix. Three matrix tablet formulations were prepared by direct compression of Kollidon SR in combination with release modifier (HPMC and Microcrystalline Cellulose) and magnesium stearate. Tablets containing only Kollidon SR with the active ingredient demonstrated a rapid rate of drug release. Incorporation of HPMC in the matrix tablet prolonged the release of drug but incorporation of Microcrystalline Cellulose showed superimposable release pattern with an initial burst effect as confirmed by mean dissolution time and Higuchi release rate data. After 7 hours of dissolution, Carvedilol release from the matrix systems were 91.42%, 83.41%, from formulation F1 and F2 respectively. Formulation F3 exhibited 100 % release at 4 hours. All the tablet formulations showed acceptable pharmaco-technical properties and complied with the in-house specifications for tablet weight variation, friability, hardness, thickness, and diameter. Prepared tablets also showed sustained release property for carvedilol. The drug release mechanism from the matrix tablets of F1 and F2 was found to be followed by Fickian and F3 by Non-Fickian mechanism.DOI: <a href="http://dx.doi.org/10.3329/icpj.v1i8.11095">http://dx.doi.org/10.3329/icpj.v1i8.11095</a> International Current Pharmaceutical Journal 2012, 1(8): 186-192

Download Full-text

Formulation and Evaluation of Galantamine Hydrobromide Floating Matrix Tablet

International Journal of Drug Delivery Technology ◽

10.25258/ijddt.v8i2.13868 ◽

2018 ◽

Vol 8 (2) ◽

Author(s):

Poreddy Srikanth Reddy ◽

Penjuri Subhash Chandra Bose ◽

Vuppula Sruthi ◽

Damineni Saritha

Keyword(s):

Sodium Alginate ◽

Xanthan Gum ◽

Lag Time ◽

Matrix Tablets ◽

In Vitro Dissolution ◽

Matrix Tablet ◽

Compression Technique ◽

Weight Variation ◽

The Matrix

The aim of the present work was to prepare floating tablets of galantamine HBr using sodium alginate and xanthan gum as matrix forming carriers. Galantamine HBr is used for the treatment of mild to moderate Alzheimer's disease and various other memory impairments, in particular those of vascular origin. The matrix tablet formulations were prepared by varying the concentrations of sodium alginate and xanthan gum. The tablets were prepared by direct compression technique using PVP K-30 as a binder and sodium bicarbonate for development of CO2. The prepared matrix tablets were evaluated for properties such as hardness, thickness, friability, weight variation, floating lag time, compatibility using DSC and FTIR. In vitro dissolution was carried out for 12 hrs in 0.1N HCl at 37±0.5 ºC using USP paddle type dissolution apparatus. It was noted that, all the prepared formulations had desired floating lag time and constantly floated on dissolution medium by maintaining the matrix integrity. The drug release from prepared tablets was found to vary with varying concentration of the polymers, sodium alginate and xanthan gum. From the study it was concluded that floating drug delivery system for galantamine HBr can be prepared by using sodium alginate and xanthan gum as a carrier.

Download Full-text

In vitro sustained release study of Thymol from Sodium Alginate Beads synthesized by Emulsion Microencapsulation

International Journal of Pharmaceutical Research ◽

10.31838/ijpr/2019.11.02.064 ◽

2019 ◽

Vol 11 (02) ◽

Keyword(s):

Sustained Release ◽

Sodium Alginate ◽

Alginate Beads ◽

Release Study

Download Full-text

Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial

Pharmaceutics ◽

10.3390/pharmaceutics13060804 ◽

2021 ◽

Vol 13 (6) ◽

pp. 804

Author(s):

Ewelina Juszczyk ◽

Kamil Kisło ◽

Paweł Żero ◽

Ewa Tratkiewicz ◽

Maciej Wieczorek ◽

...

Keyword(s):

Clinical Trial ◽

Sustained Release ◽

Development Strategy ◽

Matrix Tablets ◽

Matrix Tablet ◽

Mechanical Agitation ◽

Development Cycle ◽

Dissolution Tests ◽

Sustained Release Tablets ◽

Biopharmaceutical Properties

Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In the present study, we describe the development of a robust SR matrix tablet with a novel G-protein-coupled receptor 40 (GPR40) agonist for first-in-human studies and introduce a general workflow for the successful development of SR formulations for innovative APIs. The hydrophilic matrix tablets containing the labeled API dose of 5, 30, or 120 mg were evaluated with several methods: standard USP II dissolution, bio-predictive dissolution tests, and the texture and matrix formation analysis. The standard dissolution tests allowed preselection of the prototypes with the targeted dissolution rate, while the subsequent studies in physiologically relevant conditions revealed unwanted and potentially harmful effects, such as dose dumping under an increased mechanical agitation. The developed formulations were exceptionally robust toward the mechanical and physicochemical conditions of the bio-predictive tests and assured a comparable drug delivery rate regardless of the prandial state and dose labeled. In conclusion, the introduced development strategy, when implemented into the development cycle of SR formulations with innovative APIs, may allow not only to reduce the risk of formulation-related failure of phase I clinical trial but also effectively and timely provide safe and reliable medicines for patients in the trial and their further therapy.

Download Full-text

Sustained Release of Diltiazem Hydrochloride from Chitosan Microcapsules

Current Drug Delivery ◽

10.2174/156720109788680840 ◽

2009 ◽

Vol 6 (3) ◽

pp. 238-248 ◽

Cited By ~ 5

Author(s):

S. Farhana ◽

S. Shantakumar ◽

Laxmi Narasu

Keyword(s):

Sustained Release ◽

Diltiazem Hydrochloride

Download Full-text

Formulation and Evaluation of Sustained Release Bilayer Matrix Tablet of Glimepiride and Metformin Hydrochloride

Asian Journal of Research in Pharmaceutical Science ◽

10.52711/2231-5659.2021.00043 ◽

2021 ◽

pp. 273-279

Author(s):

Mayuri B. Patil ◽

Avish D. Maru ◽

Jayshree S. Bhadane

Keyword(s):

Sustained Release ◽

Type Ii Diabetes ◽

In Vitro Release ◽

Angle Of Repose ◽

Metformin Hydrochloride ◽

Wet Granulation ◽

Matrix Tablet ◽

Type Ii ◽

Weight Variation

The aim of the present study was to design and evaluate bilayer tablets of metformin hydrochloride as sustained release form for the treatment of Type-II diabetes mellitus. The basic aim of any Bi-layer tablet formulation is to separate physically or chemically incompatible ingredients and to produce repeat action or prolonged action of tablet. They are many drugs for treating type-II diabetes. Sulphonyl urea and biguanides are used commonly by a wide section of patients. Melt granulation process was used for the formulation of sustained comprising metformin layer and wet granulation of immediate comprising layer of glimepiride. The precompression studies like bulk density, tapped density, angle of repose, compressible index and post formulation studies includes weight variation, hardness, thickness, friability and dissolution study. The in-vitro release profile of Glimepiride was dissolved within 45 min, and Metformin Hydrochloride was able to release more than 12 hrs. They all the formulation was optimized formula due to its higher rate of dissolution and collate all other parameters with the official specifications.

Download Full-text

The Effect of Manufacturing Methods and Different Shapes on the Release Pattern of Diclofenac Sodium Matrix Tablet

Stamford Journal of Pharmaceutical Sciences ◽

10.3329/sjps.v2i2.5828 ◽

1970 ◽

Vol 2 (2) ◽

pp. 76-80

Author(s):

Tajnin Ahmed ◽

Muhammad Shahidul Islam ◽

Tasnuva Haque ◽

Mohammad Abusyed

Keyword(s):

Sustained Release ◽

Release Rate ◽

Diclofenac Sodium ◽

Matrix Tablets ◽

Wet Granulation ◽

Matrix Tablet ◽

Direct Compression ◽

Compression Method ◽

Release Pattern ◽

Peg 600

In the present study sustained release diclofenac sodium matrix tablets were prepared using Kollidon SR polymer. Hydroxypropyl methylcellulose (HPMC 15 cps) and poly ethylene glycol (PEG-600) polymers respectively were used in formulating tablets prepared by direct compression and wet granulation methods. The polymers were used to explore the release pattern of the drug into the dissolution media. The tablets were also prepared in various shapes (caplet oval, round oval and flat oval). A comparatively higher release rate of drug was obtained from the polymer HPMC 15 cps at 10% concentration for directly compressed matrix tablet than those containing 20% of HPMC after a definite period of time. In wet granulation process, 10% PEG-600 containing tablets showed a better release than those containing 20% PEG. The drug release was also found to be sustained in case of wet granulation method than that of the direct compression method. Again the caplet shaped tablets in case of direct compression method showed better release rate of drug than those of the round oval and flat oval shaped tablets. Thus the result of this study shows that the proper selection of the percentage of polymer and the suitable shape of tablet and proper manufacturing method can provide a greater opportunity in designing sustained release dosage forms. Key words: Matrix tablet; release pattern; direct compression; wet granulation; PEG 600; Kollidon SR.DOI: 10.3329/sjps.v2i2.5828Stamford Journal of Pharmaceutical Sciences Vol.2(2) 2009: 76-80

Download Full-text